Press

Mushrooms Inc (OTC:MSRM) Announces Full Patent Filing for Groundbreaking Mycelium Technology Providing Bacterial Detection and Nutrient Delivery

Oct 18 • 4 min read

Mushrooms Inc. , ( OTC: MSRM ) a leader in mycelium research and development, proudly announces the successful filing of its non-provisional patent, titled “METHOD OF GENERATING MULTIFUNCTIONAL MYCELIUM PRODUCTS”. This revolutionary patent showcases a unique approach to bacterial detection and nutrient delivery, marking a significant shift from the company’s previous provisional filing. “With the Phase 1 plan…

Lucy Scientific Discovery’s Alternative Mental Health Treatments to Provide Opportunity to Improve Mental Health

Oct 18 • 5 min read

Lucy Scientific Discovery Inc. (NASDAQ: LSDI) is a pioneer in alternative mental health treatments and looking to grab its share of the leadership mantle, as it uncovers alternative mental health treatments. From herbal remedies to psychedelics, like psilocybin and MDMA, Lucy Scientific is working to provide the ingredients for groundbreaking mental health therapies and are…

Mydecine Innovations Group gearing up for human trials after completing Aquis listing

Oct 18 • 1 min read

Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) CEO Joshua Bartch speaks to Thomas Warner from Proactive London about the biotechnology company’s ambitious goals in the psychedelic medicine sector. Bartch explains that Mydecine focuses on developing “second generation” drugs derived from first-generation psychedelic molecules like LSD, MDMA, and psilocybin. Their aim is to enhance the efficacy of these drugs while addressing challenges…

Diamond Therapeutics Announces First Patient Enrolled in FDA-authorized Study Evaluating Low-Dose Psilocybin in Human Subjects with Demoralization

Oct 17 • 4 min read

-The trial is being conducted at the University of Alabama at Birmingham (UAB) under noted psychedelic researcher Dr. Peter Hendricks- -This exploratory study is the first investigation of the influence of low-dose psilocybin on human subjects suffering from demoralization- Diamond Therapeutics Inc. (“Diamond”), a clinical-stage drug development company focused on non-hallucinogenic, psychedelic-based therapies for use in the treatment…

Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure

Oct 17 • 2 min read

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has entered into an agreement with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441